Imaging biomarker roadmap for cancer studies.
- O'Connor, JPB
- Aboagye, EO
- Adams, JE
- Aerts, HJWL
- Barrington, SF
- Beer, AJ
- Boellaard, R
- Bohndiek, SE
- Brady, M
- Brown, G
- Buckley, DL
- Chenevert, TL
- Clarke, LP
- Collette, S
- Cook, GJ
- deSouza, NM
- Dickson, JC
- Dive, C
- Evelhoch, JL
- Faivre-Finn, C
- Gallagher, FA
- Gilbert, FJ
- Gillies, RJ
- Goh, V
- Griffiths, JR
- Groves, AM
- Halligan, S
- Harris, AL
- Hawkes, DJ
- Hoekstra, OS
- Huang, EP
- Hutton, BF
- Jackson, EF
- Jayson, GC
- Jones, A
- Koh, D-M
- Lacombe, D
- Lambin, P
- Lassau, N
- Leach, MO
- Lee, T-Y
- Leen, EL
- Lewis, JS
- Liu, Y
- Lythgoe, MF
- Manoharan, P
- Maxwell, RJ
- Miles, KA
- Morgan, B
- Morris, S
- Ng, T
- Padhani, AR
- Parker, GJM
- Partridge, M
- Pathak, AP
- Peet, AC
- Punwani, S
- Reynolds, AR
- Robinson, SP
- Shankar, LK
- Sharma, RA
- Soloviev, D
- Stroobants, S
- Sullivan, DC
- Taylor, SA
- Tofts, PS
- Tozer, GM
- van Herk, M
- Walker-Samuel, S
- Wason, J
- Williams, KJ
- Workman, P
- Yankeelov, TE
- Brindle, KM
- McShane, LM
- Jackson, A
- Waterton, JC
DOIAbstract
Imaging biomarkers (IBs) are integral to the routine management of patients with cancer. IBs used daily in oncology include clinical TNM stage, objective response and left ventricular ejection fraction. Other CT, MRI, PET and ultrasonography biomarkers are used extensively in cancer research and drug development. New IBs need to be established either as useful tools for testing research hypotheses in clinical trials and research studies, or as clinical decision-making tools for use in healthcare, by crossing 'translational gaps' through validation and qualification. Important differences exist between IBs and biospecimen-derived biomarkers and, therefore, the development of IBs requires a tailored 'roadmap'. Recognizing this need, Cancer Re...
Add to ORKG